Havah has completed world leading pre-clinical and clinical trials (Phase I,II and III) to develop androgen-based pharmaceuticals for use in breast disease.
Havah is one of the first biotechs to utilize the breast tissue specific innate hormone/immune interface.
Androgens are an essential hormone in both men and women-the balance between estrogens and androgens is critical in the maintenance of hormonal homeostasis and the interface between hormonal function and the immune system.
Havah Therapeutics lead product delivers a unique androgen product to effect a beneficial tissue specific alteration in estrogen:androgen ratio and reduce breast tissue autoimmune inflammation
“As no approved female product is presently approved by a national regulatory body, the panel highlighted the pressing need for more research into testosterone therapy for women and the development and licensing of products indicated specifically for women.”
Founder and inventor, 30-year breast cancer specialist/surgeon and renowned medical innovator, clinical oncologist, widely published molecular oncologist in leading journals incl. Nature, founder/ pioneer of three leading (Australian) multi-disciplinary breast centres in both the public and private sectors. Dr Birrell, with his scientific research partner, Prof Wayne Tilley, are internationally recognized for pioneering the use of androgens in breast disease.
Joe Schacter, Business Development
Dr Stephen Birrell talk about testosterone in gynaecology at a National Meeting June 4th 2022